Profound Medical Corp. (PROF)
| Market Cap | 309.68M |
| Revenue (ttm) | 5.21M |
| Net Income (ttm) | -20.58M |
| Shares Out | 20.35M |
| EPS (ttm) | -1.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $15.22 |
| Previous Close | $15.21 |
| Change ($) | 0.01 |
| Change (%) | 0.07% |
| Day's Open | 15.20 |
| Day's Range | 14.50 - 15.28 |
| Day's Volume | 57,253 |
| 52-Week Range | 13.70 - 28.97 |
TORONTO, July 22, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, ...
TORONTO, July 15, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, ...
TORONTO, May 25, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...
TORONTO, May 19, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual Meeting of Shareholders ...
TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, i...
PROFOUND MEDICL (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TORONTO, April 21, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...
TORONTO, April 14, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...
TORONTO, March 03, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free th...
PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -40.74% and -4.95%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...
TORONTO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free the...
TORONTO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free the...
TORONTO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free the...
I have put an emphasis on value in 2021; however, I am not sitting still in my aggressive portfolio. I have added 2 new positions and added to a third. All 3 companies look to benefit from a return to n...
TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free the...
TORONTO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine re...
TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administration (“FD...
TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine re...
Profound Medical has unique differentiators via their TULSA-PRO procedure that provide a breakthrough in an otherwise complex treatment domain. The company has faced headwinds from COVID-19 this year, b...
TORONTO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine re...
Profound Medical Corp. (PROF) CEO Arun Menawat on Q3 2020 Results - Earnings Call Transcript
TORONTO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine re...
TORONTO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine re...
TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combi...
Profound Medical: Momentum Continues To Build
TORONTO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combin...
Profound Medical Corp. (PROF) CEO Arun Menawat on Q2 2020 Results - Earnings Call Transcript
PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -43.48% and -1.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combin...
TORONTO, July 22, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combin...
TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it has closed its previously-announced underwritten ...
TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the pricing of an underwritten public offering (the “Offe...
TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it intends to file a preliminary prospectus suppleme...
Profound Medical (PROF) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
TULSA-PRO, the most flexible prostate treatment on the market.
TORONTO, May 20, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of...
Profound Medical Corp. (PROF) CEO Dr.
PROFOUND MEDICL (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Profound Medical: The Prostate Market Disruptor
Profound Medical, The Apple Of The Prostate Arena
TORONTO, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free...
Profound Medical: Non-Surgical Prostatectomy Is Profound
TORONTO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free...
About PROF
Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with me... [Read more...]
| Industry Medical Devices | |
| Stock Exchange NASDAQ | Ticker Symbol PROF |
Financial Performance
In 2020, PROF's revenue was 7.30 million, an increase of 74.99% compared to the previous year's 4.17 million. Losses were -21.62 million, 42.0% more than in 2019.